Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets [Abstract]
Cash and cash equivalents	$ 11,973,647	$ 23,367,456
Prepaid clinical trial costs	779,602	78,295
Prepaid expenses and other current assets	743,381	254,637
Total Assets	13,496,630	23,700,388
Liabilities [Abstract]
Short-term debt	332,000	0
Accounts payable	5,720,455	3,849,108
Accrued clinical expenses	6,845,910	11,966,812
Accrued compensation	1,216,237	958,607
Other accrued liabilities	377,367	400,490
Total current liabilities	14,491,969	17,175,017
Warrant liabilities	350,478	806,655
Total Liabilities	14,842,447	17,981,672
Commitments and Contingencies
Stockholders' Equity (Deficit)
Common stock, par value of $0.0001; 115,000,000 shares authorized; 27,918,560 issued and outstanding as of March 31, 2024 and December 31, 2023	2,792	2,792
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	140,439,247	140,070,172
Accumulated deficit	(141,787,856)	(134,354,248)
Total stockholders' equity (deficit)	(1,345,817)	5,718,716
Total Liabilities and Stockholders' Equity (Deficit)	$ 13,496,630	$ 23,700,388